.jpeg)
2026-08-31 03:59:58
Capmatinib is a highly selective MET inhibitor for metastatic NSCLC harboring MET exon 14 skipping mutations, with efficacy established by the GEOMETRY mono-1 trial in both first-line and previously treated settings.
2026-08-31 03:37:12
The combination is approved for first-line treatment of locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R substitutions, with PFS and OS advantages over osimertinib in MARIPOSA.
2026-08-31 03:26:31
Lapatinib is an oral reversible dual EGFR/HER2 tyrosine kinase inhibitor used in previously treated HER2-positive advanced or metastatic breast cancer to delay disease progression.
2026-08-27 07:05:19
Mirdametinib is a MEK1/2 inhibitor approved by the FDA for symptomatic, inoperable plexiform neurofibromas in patients with NF1 aged 2 years and older. This article explains its mechanism, ReNeu trial data, and targeted therapy value.
2026-08-26 07:44:33
Acalabrutinib is a selective oral BTK inhibitor for B-cell malignancies like CLL. This article outlines its twice-daily dosing, the timeline for efficacy evaluation, and the importance of adherence.
2026-08-26 07:21:45
Osimertinib (brand name: TAGRISSO) is a third-generation EGFR tyrosine kinase inhibitor for EGFR-mutant NSCLC. This article reviews its clinical efficacy, food administration advice, tablet handling, and key safety precautions.
2026-08-26 07:10:57
Ceritinib (brand name: Zykadia) is a second-generation oral ALK tyrosine kinase inhibitor for ALK-positive non-small cell lung cancer. This guide outlines the recommended 450mg once-daily dosing with food, dose modification principles, and missed-dose protocols to support safe and effective treatment.
2026-08-26 07:08:08
Ruxolitinib is a JAK1/JAK2 inhibitor used in myelofibrosis and other myeloproliferative neoplasms. This guide outlines drug interactions involving CYP3A4/CYP2C9, dosing considerations in hepatic impairment, and safety precautions during infection.
2026-08-25 08:10:21
Belzutifan (WELIREG) is a first-in-class oral HIF-2α inhibitor approved for VHL-associated renal cell carcinoma, CNS hemangioblastomas, and pancreatic neuroendocrine tumors. This guide outlines dosing, time to response, follow-up schedules, discontinuation criteria, and long-term management strategies for patients and clinicians.
2026-08-24 07:51:59
Lapatinib is an oral dual HER2/EGFR tyrosine kinase inhibitor. Key adverse effects to monitor during treatment include diarrhea, skin reactions, and hepatic function changes. This article outlines recognition points and graded management strategies.
2026-08-21 03:30:56
Cemiplimab is a PD-1 immune checkpoint inhibitor that restores T-cell antitumor immunity. It is FDA-approved for advanced basal cell carcinoma, cutaneous squamous cell carcinoma, and selected cases of non-small cell lung cancer.
2026-08-20 03:48:01
Capmatinib (brand name Tabrecta) is a highly selective MET tyrosine kinase inhibitor developed by Novartis, approved for adults with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations. This article systematically examines its positioning as a second-generation MET inhibitor with superior selectivity and intracranial activity, provides detailed adverse effect incidence data from the pivotal GEOMETRY mono-1 trial, and presents grade-based management strategies for peripheral edema, hepatotoxicity, gastrointestinal effects, and other toxicities, along with dose-modification protocols and special-population guidance to support safe and effective targeted therapy.
